Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

Burrill Predicts Better Time' Ahead For Biotech Industry

Sep. 25, 2003

By Aaron Lorenzo

Burrill Predicts Better Time' Ahead For Biotech Industry

Sep. 25, 2003

By Aaron Lorenzo

ParAllele's Second Round Raises $22.5M For Commercial Growth

Sep. 24, 2003

By Aaron Lorenzo

Anticipating Ceplene Approval, Maxim Raises $25.5M Privately

Sep. 24, 2003

By Aaron Lorenzo

ParAllele's Second Round Raises $22.5M For Commercial Growth

Sep. 24, 2003

By Aaron Lorenzo

Anticipating Ceplene Approval, Maxim Raises $25.5M Privately

Sep. 24, 2003

By Aaron Lorenzo

First-Round Financing Of $12.5M Puts Ambrx On Development Path

Sep. 23, 2003

By Aaron Lorenzo

First-Round Financing Of $12.5M Puts Ambrx On Development Path

Sep. 23, 2003

By Aaron Lorenzo

IntraBiotics Receives FDA Nod To Proceed With Pivotal Trials

Sep. 22, 2003

By Aaron Lorenzo

Stock values continued to soar all last week for IntraBiotics Pharmaceuticals Inc. on two news items related to its lead product, iseganan hydrochloride, the latest of which outlined a special protocol assessment agreement with the FDA. (BioWorld Today)

IntraBiotics Receives FDA Nod To Proceed With Pivotal Trials

Sep. 22, 2003

By Aaron Lorenzo

Stock values continued to soar all last week for IntraBiotics Pharmaceuticals Inc. on two news items related to its lead product, iseganan hydrochloride, the latest of which outlined a special protocol assessment agreement with the FDA. (BioWorld Today)